Afterload reduction therapy in acute and chronic ischemic heart disease.
D001337:Autonomic Agents / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D004298:Dopamine / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D009566:Nitrates / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D001337:Autonomic Agents; D006834:Hydrazines; D009566:Nitrates; D011799:Quinazolines; D014665:Vasodilator Agents; D009599:Nitroprusside; D005996:Nitroglycerin; D004298:Dopamine; D011224:Prazosin; D010646:Phentolamine